Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP1011T in advanced solid tumors
NCT07321574Phase 2Recruiting
- Sponsor
- Shanghai AB PharmaTech
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ABP1011T in small cell lung cancer (SCLC), esophageal cancer, Cervical Cancer (CC), bladder cancer, renal cell carcinoma (RCC), sponsored by Shanghai AB PharmaTech. Started Dec 2025; status: recruiting.
02
Drugs
ABP1011T
03
Conditions
small cell lung cancer (SCLC)esophageal cancerCervical Cancer (CC)bladder cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07321574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321574.